Sponsors (6)
This resolution exposes risks in a proposed OMB rule—improving transparency and arguments to protect health-equity research—but highlights trade-offs where expanding political control over grants and restricting DEI-related and international research could undermine scientific freedom, competitiveness, and health outcomes for marginalized groups.
Racial and ethnic minority groups and women: the resolution highlights potential harms to health equity and the economic costs of disparities, strengthening arguments to preserve federal funding for minority health and related research.
Researchers and the public: the resolution produces clearer findings about how the proposed OMB rule could weaken peer review and grant oversight, increasing transparency and prompting possible congressional or administrative pushback.
Taxpayers and federal employees: the proposed expansion of OMB authority could concentrate policymaking in political appointees, bypassing congressional intent and reducing transparency and accountability.
Women, racial and ethnic minorities, and LGBTQ individuals: banning federal-funded DEI and related gender research risks worsening their underrepresentation in clinical studies and harming health outcomes.
Scientists, researchers, and students: increased political oversight and the possibility of mid-award grant terminations without appeal could disrupt ongoing studies, careers, and training.
Based on analysis of 1 section of legislative text.
Registers congressional objection to an OMB rule/EO that would expand political oversight of grants, weaken peer review, restrict collaborations, and limit DEI-funded research and publication costs.
Official title: Recognizing that equity, diversity, and inclusion in federally funded health research is necessary to enhance scientific excellence, and ensure equitable outcomes for patients in the United States.
Introduced July 16, 2026 by Debbie Dingell · Last progress July 16, 2026
Declares congressional objection to a proposed OMB rule and related Executive Order that would expand OMB authority over federal policymaking and grant administration, increase political appointee oversight of grants, weaken peer review, restrict meeting attendance and international collaborations, bar certain foreign collaborations, and prohibit use of grant funds for publication costs. Warns these changes could allow mid-award grant termination without appeal, limit research on diversity, equity, and inclusion (DEI), threaten agencies and programs serving underrepresented groups, harm research quality, and increase health and economic disparities.